FORM 1449*

INFORMATION DISCLOSURE STATEMENT

Docket Number: 05822.0319USWO Application Number: 10/521,038

IN AN APPLICATION

Applicant: ROOS et al.

(Use several sheets if necessary)

Filing Date: 31 October 2005 Group Art Unit: 1657

		U	S. PATENT DOCUMEN	TS				
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		FOR	EIGN PATENT DOCUM	IENTS				
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
	OTHER	DOCUMENTS	(Including Author, Title,	Date, Pertinent I	Pages, Etc.)	<u> </u>		
	7. Comple	Horiuchi et al. "II. Progress in diagnosis of connective tissue disease and understanding of its clinical condition, 7. Complement." <i>Jr. of the Japanese Society of Internal Medicine. Vol. 87. No. 12.</i> 1998. pp. 2427-2433. (No Translation)						
		Fujita et al. "Recent Progress for molecular mechanism of protection against infection-Role complement-lectin pathway in protection against infection. <i>Clinical Immunity. Vol. 35. No. 1.</i> 2001. pp. 38-43. (No Translation)						
	Studies wi	Hoekzema et al. "The Distortive Mechanism for the Activation of Complement Component C1 Supported by Studies with a Monoclonal Antibody Against the "Arms" of C1q." <i>Molecular Immunology. Vol. 25. No. 5.</i> 1988. pp. 485-494.						
		Collard et al. "Complement Activation after Oxidative Stress: Role of the Lectin Complement Pathway." Am. Jr. of Pathology. Vol. 156. No. 5. 2000. pp.1549-1556.						

23552
PATENT TRADEMARK OFFICE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LJH/

EXAMINER

/Lisa Hobbs/

DATE CONSIDERED

01/19/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.